• DeferoxamineB in Cancer Research: Protocols and Troubleshoot

  2026-07-07

  Deferoxamine (DeferoxamineB) stands out as a robust iron chelator and apoptosis/autophagy inducer, crucial for advanced cancer models targeting regulated cell death pathways. This guide delivers actionable protocols, troubleshooting strategies, and workflow enhancements, all grounded in cutting-edge metabolic intervention research.

• Cimetidine as a Histamine-2 Receptor Antagonist in Advanced

  2026-07-07

  Cimetidine stands apart as a histamine-2 receptor antagonist with partial agonist activity, enabling sophisticated blood-brain barrier and cancer research. Leveraging recent surrogate barrier model breakthroughs, researchers can now optimize permeability assays and antitumor studies using APExBIO’s high-purity Cimetidine.

• Praeruptorin A: Applied Protocols for Inflammation & Cancer

  2026-07-06

  Praeruptorin A, an angular pyranocoumarin compound, empowers researchers to dissect inflammation, ferroptosis, and cancer metastasis with unparalleled mechanistic precision. This article translates advanced bench findings into actionable workflows, protocol refinements, and troubleshooting strategies for translational discovery.

• Amyloid Beta-peptide (25-35): Decoding Microglial Responses

  2026-07-06

  Explore how Amyloid Beta-peptide (25-35) (Aβ25-35) models neuroinflammation and microglial polarization in Alzheimer's disease. This article offers a unique, mechanistic perspective for advanced neurodegenerative disease research.

• Kanamycin Sulfate: Water-Soluble Antibiotic for Research Use

  2026-07-05

  Kanamycin Sulfate is a high-purity, water-soluble aminoglycoside antibiotic widely used in microbiology and antibiotic resistance research. Its precise mechanism targets bacterial protein synthesis, ensuring reproducibility in cell selection and anti-infection studies.

• Applied Use of Aprotinin (BPTI) in Fibrinolysis and Genomic

  2026-07-04

  Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI) bridges advanced blood management with next-generation molecular assays. This article delivers actionable workflow enhancements, troubleshooting guidance, and protocol-specific best practices that unlock the full experimental value of APExBIO's Aprotinin in both protease modulation and nascent RNA profiling.

• Translational Leverage of Fluorouracil: Mechanisms to Strate

  2026-07-03

  This thought-leadership article explores the molecular and translational landscape of Fluorouracil (Adrucil) in solid tumor research. Integrating mechanistic insights, recent evidence on cancer stemness, and strategic workflow guidance, it positions APExBIO's Fluorouracil as a next-generation standard for high-impact oncology studies.

• Gepotidacin (GSK2140944): Optimizing Antibacterial Research

  2026-07-03

  Gepotidacin (GSK2140944) enables precise inhibition of bacterial DNA replication, uniquely targeting resistant pathogens where fluoroquinolones fail. This guide delivers data-driven workflows, troubleshooting strategies, and comparative insights to maximize experimental reliability across modern antibacterial research.

• Talabostat Mesylate (PT-100): Unlocking DPP4 and FAP Inhibit

  2026-07-02

  Explore the advanced mechanisms of Talabostat mesylate (PT-100) as a DPP4 and FAP inhibitor in cancer research. This article delves into emerging insights on immune modulation and assay design, offering a unique perspective beyond standard protocols.

• High-Throughput BBB Permeability Prediction Using Surrogate

  2026-07-02

  This study establishes a high-throughput in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells, integrating lysosomal trapping correction to improve permeability prediction. The model demonstrates strong correlation with in vivo brain distribution, offering a practical tool for early-stage CNS drug screening and mechanistic studies.

• PARP7 Inhibition Restores IFN-I Signaling in EAE Mouse Model

  2026-07-01

  The study by Xu et al. demonstrates that PARP7 suppresses type I interferon signaling by promoting autophagic degradation of STAT1 and STAT2, with inhibition of PARP7 alleviating neuroinflammation in experimental autoimmune encephalomyelitis (EAE) mouse models. These findings reveal a previously unappreciated regulatory axis in neuroinflammation and suggest therapeutic potential for targeting PARP7 in multiple sclerosis research.

• Phenytoin in Translational Neuroscience: Precision Tools, St

  2026-07-01

  This thought-leadership article explores the mechanistic and translational value of Phenytoin (5,5-diphenylimidazolidine-2,4-dione) for sodium channel modulation research. Anchored in recent biochemical and neurological disease model data, it provides actionable protocol guidance, competitive insight, and strategic outlooks tailored for researchers bridging basic and clinical science.

• Cycloheximide in Proteostasis Research: Precision, Limitatio

  2026-06-30

  Explore the unique role of Cycloheximide as a protein biosynthesis inhibitor in unraveling eukaryotic proteostasis and apoptosis. This article provides advanced scientific context, practical protocol guidance, and insights from the latest translational research.

• Modeling Neuro-Cardiac Pacemaker Maturation with Human Assem

  2026-06-30

  This study introduces a human-specific in vitro assembloid platform that integrates pluripotent stem cell-derived sinoatrial node (SAN) and cardiac plexus organoids. The model enables detailed mechanistic analysis of neuro-cardiac signaling and pacemaker maturation, providing new opportunities to investigate human conduction disorders and autonomic regulation.

• Pericyte-Targeting Prodrug Strategy Overcomes VDA Resistance

  2026-06-29

  The reference study demonstrates that engineering a vascular disrupting agent (VDA) prodrug to target tumor pericytes—rather than endothelial cells—effectively eliminates the previously resistant viable rim in tumors, resulting in complete regression in xenograft models. This innovation leverages selective activation by fibroblast activation protein α (FAPα), offering a new direction for overcoming intrinsic resistance to VDAs and reshaping tumor microenvironment modulation strategies.

16336 records 1/1090 page Next 12345 下5页 Last page